相关临床试验
76
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
1.3%
已完成
57
75.0%
尚未招募
1
1.3%
招募中
8
10.5%
终止
6
7.9%
撤回
2
2.6%
Withheld
1
1.3%
暂无批准数据
- The global body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031, at a CAGR of 6.9%. - Consumables dominated the market with a 70.4% share in 2025, while immunoassay technology is expected to register the highest growth rate during the forecast period. - Cerebrospinal fluid analysis led the market by fluid type at 29.1% share in 2025, driven by expanding neurological disease evaluation and biomarker-based testing. - North America held the largest regional market share in 2025, while Asia Pacific is expected to be the fastest-growing region through 2031.
- The global molecular diagnostics market is projected to grow from USD 19.48 billion in 2025 to USD 30.74 billion by 2030, at a CAGR of 9.6%, according to MarketsandMarkets. - PCR and real-time PCR technologies dominate the market with a 42.54% revenue share, while sequencing-based testing is the fastest-growing segment due to personalized medicine adoption. - North America leads the global market with a 38.49% share, while Asia Pacific is the fastest-growing region with an estimated CAGR of 24.45% through 2035. - Key players including Roche, Danaher, Abbott, and Thermo Fisher are investing in automation, AI-powered analytics, and multiplex assay development to strengthen competitive positioning.
- BD commercially launched the CentroVena One™ Insertion System, the first all-in-one central venous catheter insertion device designed to simplify central line placement for clinicians. - The system reduces procedural steps by 30% and insertion time by 50% compared to traditional methods, while minimizing contamination risk and insertion-related complications. - The device received FDA 510(k) clearance and was accepted into the FDA Safer Technologies Program, marking BD's entry into the acute CVC market. - UNC Health Blue Ridge is among the first health systems to pilot the system, with early clinical evaluation showing streamlined catheter placement and reduced opportunities for error.
- Waters Corporation announced FDA 510(k) clearance for the BD BACTEC FXI Culture System, enabling U.S. commercialization of the next-generation automated blood culture platform. - Clinical study data demonstrated the system achieves approximately 3-hour faster time to detection (~15% reduction) compared to the previous-generation system, potentially improving sepsis patient outcomes. - The system features industry-leading automation with 50% increased vial loading capacity and first-of-its-kind automated gravimetric blood volume measurement to improve diagnostic consistency. - The platform addresses critical clinical needs as each hour of delayed sepsis treatment increases mortality by 3.6% to 9.9%, making faster diagnostic workflows essential in acute care settings.
- Waters Corporation announced FDA clearance of the Onclarity HPV Self-Collection Kit, marking a significant milestone in expanding access to cervical cancer screening by removing barriers that prevent routine screening. - The kit utilizes the BD Onclarity HPV Assay, the most comprehensive FDA-approved HPV screening tool in the U.S., which detects all high-risk carcinogenic HPV genotypes with extended genotyping capabilities. - Approximately 60% of cervical cancer cases occur in individuals who are unscreened or under-screened, making at-home self-collection a critical strategy for improving early detection and reducing cervical cancer deaths. - The kit will be available by prescription and covered by private insurance, Medicaid, and Medicare, allowing patients to collect samples at home and mail them to laboratories for processing.
- BD announced the European launch of its Pyxis Pro Dispensing Solution and Incada Connected Care Platform, combining advanced automation with AI-driven insights for medication management. - The system offers enhanced medication storage capacity in a similar footprint, improved security features for controlled substances, and streamlined medication retrieval through RFID badge scanning and wireless barcode scanners. - The AI-powered BD Incada Analytics platform will extend to European hospitals next year, providing enterprise-wide visibility into medication inventory and customizable dashboards to reduce waste and improve efficiency. - BD will leverage AWS European Sovereign Cloud to meet EU healthcare systems' digital sovereignty requirements while maintaining performance and security standards.
- BD (Becton, Dickinson and Company) has received CE Mark approval in the European Union for its Revello Vascular Covered Stent, designed to treat atherosclerotic lesions in the common and external iliac arteries. - The company has completed enrollment of 118 patients in the iliac artery cohort of the AGILITY clinical study, with total enrollment expected to exceed 300 participants across multiple regions. - The Revello stent combines a self-expanding nitinol stent with an ultrathin expanded polytetrafluoroethylene covering and features a tri-axial delivery system for controlled deployment. - The global peripheral arterial disease treatment market is projected to grow from $3.17 billion in 2025 to $6.11 billion by 2034, expanding at a CAGR of 7.56%.
- BD received 510(k) clearance from the FDA for Surgiphor™ 1000mL, marking the first and only 1000mL antimicrobial irrigation system specifically designed for powered lavage procedures. - The ready-to-use sterile solution eliminates the need for hospital staff to manually mix solutions, saving valuable operating room time while meeting global safety guidelines for surgical wound cleaning. - Surgiphor™ 1000mL is compatible with commonly used powered lavage devices and includes versatile features like a powered-device adapter and Y-connector for seamless integration into existing OR workflows. - The expanded Surgiphor™ portfolio now offers both manual and powered irrigation configurations, providing clinicians with flexibility to match their specific workflow and patient population needs.
- BD received FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, a state-of-the-art multi-modality platform designed to enhance breast disease diagnosis. - The system features advanced capabilities including high and low vacuum strengths, 360-degree sampling ability, and multiple probe options to accommodate different lesion types across various breast imaging modalities. - The device is expected to enter the market in early 2026, expanding BD's breast health portfolio and supporting early detection and diagnosis of breast disease. - Key features include multi-modality compatibility, variable sample notch adjustment during procedures, enhanced visualization tools, and choice of 12G, 10G, and 7G probes for different clinical needs.
- BD announced a $110 million investment to expand prefillable syringe production in Columbus, Nebraska, creating approximately 120 new jobs and supporting pharmaceutical reshoring efforts. - The investment will establish BD Neopak™ Glass Prefillable Syringe production to meet growing demand for biologics and GLP-1 medications like Ozempic and Wegovy. - This expansion is part of BD's broader $2.5 billion commitment to U.S. manufacturing over the next five years, strengthening domestic supply chain resilience. - Production is expected to begin in mid-2026, with the facility supporting both clinical and at-home drug delivery applications through autoinjector integration.
